The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium will enroll patients with sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The goals of the CReATe consortium are to advance therapeutic development for this group of neurodegenerative disorders through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers.
Research survey for rare disease patients and their families about impacts of COVID-19
How is the novel coronavirus pandemic impacting people with rare diseases and their families? Complete the 20-minute research survey from home or learn more at this link.
CReATe Issues 2020 Pilot Project Request for Applications
The CReATe Consortium in partnership with the ALS Association has released a Biomarker Pilot Project Request for Applications (RFA). The submission deadline for Letters of Intent is January 17, 2020. Click here for details